Skip to main content
main-content

06-06-2021 | ASCO 2021 | Conference coverage | Video

Adjuvant pembrolizumab improves RCC disease-free survival

Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma (3:03).

Read transcript

Related content

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits